XOMA Corp. Price Target Increased to $13.00 by Analysts at Wedbush (XOMA)
Equities research analysts at Wedbush increased their price objective on shares of XOMA Corp. (NASDAQ:XOMA) to $13.00 in a research note issued to investors on Wednesday, AnalystRatings.NET reports. Wedbush’s price target suggests a potential upside of 70.38% from the company’s current price.
A number of other analysts have also recently weighed in on XOMA. Analysts at Jefferies Group initiated coverage on shares of XOMA Corp. in a research note to investors on Thursday, January 9th. They set a “buy” rating and a $11.00 price target on the stock. Separately, analysts at Roth Capital raised their price target on shares of XOMA Corp. from $6.00 to $8.00 in a research note to investors on Friday, November 1st. They now have a “buy” rating on the stock. Finally, analysts at Credit Suisse raised their price target on shares of XOMA Corp. from $5.00 to $8.00 in a research note to investors on Friday, November 1st. They now have an “outperform” rating on the stock. Eight research analysts have rated the stock with a buy rating, XOMA Corp. has an average rating of “Buy” and a consensus target price of $8.78.
XOMA Corp. (NASDAQ:XOMA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.21) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.18) by $0.03. The company had revenue of $6.31 million for the quarter, compared to the consensus estimate of $7.87 million. During the same quarter last year, the company posted ($0.39) earnings per share. XOMA Corp.’s revenue was down 13.0% compared to the same quarter last year.
In other XOMA Corp. news, CEO John Varian sold 10,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $8.28, for a total transaction of $82,800.00. Following the completion of the sale, the chief executive officer now directly owns 148,739 shares in the company, valued at approximately $1,231,559. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
XOMA Corporation (NASDAQ:XOMA) is engaged in the discovery and development of antibody-based therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.